glp 1 neuroinflammation Glucagon-like peptide-1 medicines in neurological and psychiatric disorders: Cell Reports Medicine GLP-1 Receptor Agonists – Peripheral

In the landmark 68-week STEP-1 trial, adults with overweight or obesity who reached the 2.4 mg maintenance dose lost roughly 15% of their body weight on average a magnitude that had previously belonged to bariatric surgery, not an injection

Seker A, Seker A

Men nr GLP-1-substanser kps frn oklara kllor, anvnds utan uppfljning eller doseras fel kar riskerna

The most commonly reported GI AEs include nausea, diarrhoea, vomiting, and constipation, which are typically mild to moderate in intensity and transient in duration [13, 38, 40,41,42,43,44,45,46, 52]

In conclusion, the FDA approval of Zepbound for OSA represents a paradigm shift in sleep apnea treatment

Do not self-inject it